The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PLYX | N/A | N/A | N/A | +0% |
| S&P | +14.29% | +86.82% | +13.3% | -0% |
No news articles found for Polaryx Therapeutics.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | $0.00K | 0.0% |
| Employees | 11 | 0.0% |
| Net Income | -$1,430.00K | 0.0% |
| EBITDA | -$974.00K | 0.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $5.75M | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | 0.0% |
| Short Term Debt | $0.00K | 0.0% |
No data available for this period.
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$887.00K | 0.0% |
| Operating Free Cash Flow | -$887.00K | 0.0% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|
| Total Debt | $0.00K | $0.00K | $0.00K | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
